The effect of antithrombin added to recombinant human-soluble thrombomodulin for severe community-acquired pneumonia-associated disseminated intravascular coagulation: a retrospective cohort study using a nationwide inpatient database
Open Access
- 13 January 2020
- journal article
- research article
- Published by Springer Nature in Journal of Intensive Care
- Vol. 8 (1) , 1-8
Abstract
Background: Studies showed potential benefits of recombinant human-soluble thrombomodulin (rhTM) and antithrombin for treating sepsis associated disseminated intravascular coagulation. However, benefits of their combination have been inconclusive. Methods: Using a nationwide inpatient database in Japan, we performed propensity-score matched analyses to compare outcomes between rhTM combined with antithrombin and rhTM alone for severe community-acquired pneumonia associated disseminated intravascular coagulation from July 2010 to March 2015. The outcomes included in-hospital mortality and requirement of red cell transfusion. Results: Propensity score matching created 189 pairs of patients who received rhTM combined with antithrombin or rhTM alone within 2 days of admission. There was no significant difference between the two groups for in-hospital mortality (40.2% vs. 45.5%). Patients treated with rhTM and antithrombin were more likely to require red cell transfusion than those treated with rhTM alone (37.0% vs. 25.9%). Conclusions: Compared with rhTM alone, combination of rhTM with antithrombin for severe community-acquired pneumonia-associated disseminated intravascular coagulation may be ineffective for reducing mortality and may increase bleeding.Keywords
Funding Information
- Ministry of Health, Labour and Welfare (H29-Policy-Designated-009 and H29-ICT-General-004)
- Ministry of Education, Culture, Sports, Science and Technology, Japan (17H04141 and 16K09254)
- Japan Agency for Medical Research and Development
This publication has 38 references indexed in Scilit:
- A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsisCritical Care, 2013
- The eye response test alone is sufficient to predict stroke outcome—reintroduction of Japan Coma Scale: a cohort studyBMJ Open, 2013
- Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysisIntensive Care Medicine, 2013
- Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammationJournal of Thrombosis and Haemostasis, 2011
- Propensity Score Adjustment With Multilevel Data: Setting Your Sites on Decreasing Selection BiasAnnals of Internal Medicine, 2010
- Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samplesStatistics in Medicine, 2009
- Guidelines for the diagnosis and management of disseminated intravascular coagulationBritish Journal of Haematology, 2009
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in AdultsClinical Infectious Diseases, 2007
- Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trialJournal of Thrombosis and Haemostasis, 2006
- High-Dose Antithrombin III in Severe SepsisJAMA, 2001